SMARCA2 and small cell lung carcinoma: AU-15330 treatment resulted in time and dose-dependentdegradation of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1 in cell linesencompassing different molecular subtypes of SCLC (Figures 1E and S1C).